The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma is scheduled to report its third quarter 2026 financial results. The stock is little changed on the day, trading near $34.4.
UroGen Pharma announced it will report its third quarter 2026 financial results. The company also said it will host a live earnings call at 10:00 AM ET. Of the 32 analysts covering the stock, 28 rate it a buy and none rate it a sell.
View post on X Loading...
UroGen Pharma stock opened with a gap up from $34.36 to $34.78 before giving back part of that advance. The price remains confined beneath the MA-20 and MA-50 but is still holding above the MA-200, reflecting a split daily structure. RSI at 38.9 is nearing oversold territory, which suggests that recent declines are starting to reach a stretched condition. The nearest resistance is the weekly high at $34.94.
A close above $34.94 would indicate buyers are ready to continue the move, while a drop below $32.4 would show the advance is being faded. In today's session the stock opened with a gap up from $34.36 to $34.78, but has since surrendered a portion of those gains. Although the past week saw a sustained move higher with a firm trend, from here downside probability stands at 58% and upside at 42% for the coming trading week. The expected trading range is $33.26 to $35.53. On the weekly chart the longer-term picture stays constructive.
Earlier, analysts noted that UroGen Pharma's technical outlook had shifted to increased downside risk as shares hovered near key support. The upcoming earnings release adds a potential catalyst to this setup, with traders now focused on whether the stock can decisively move above $34.94 resistance or risks slipping back toward the $33.26–$35.53 expected trading range in the coming week.